176 related articles for article (PubMed ID: 28844154)
21. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology, Risk Factors, and Outcomes After Early Posttransplant
Jorgenson MR; Descourouez JL; Yang DY; Leverson GE; Saddler CM; Smith JA; Safdar N; Mandlebrot DA; Redfield RR
Ann Pharmacother; 2019 Oct; 53(10):1020-1025. PubMed ID: 31007034
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.
Mani S; Rybicki L; Jagadeesh D; Mossad SB
Bone Marrow Transplant; 2016 May; 51(5):713-7. PubMed ID: 26726944
[TBL] [Abstract][Full Text] [Related]
25. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center.
Tsapepas DS; Martin ST; Miao J; Shah SA; Scheffert J; Fester K; Ma K; Lat A; Egan R; McKeen JT
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):299-304. PubMed ID: 25586932
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients.
Neofytos D; Kobayashi K; Alonso CD; Cady-Reh J; Lepley D; Harris M; Desai N; Kraus E; Subramanian A; Treadway S; Ostrander D; Thompson C; Marr K
Transpl Infect Dis; 2013 Apr; 15(2):134-41. PubMed ID: 23173772
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections.
Jamot S; Raghunathan V; Patel K; Kelly CR; Lim SH
Infect Control Hosp Epidemiol; 2018 Mar; 39(3):302-306. PubMed ID: 29363436
[TBL] [Abstract][Full Text] [Related]
29. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
Brown CC; Manis MM; Bohm NM; Curry SR
Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
Brandt LJ; Aroniadis OC; Mellow M; Kanatzar A; Kelly C; Park T; Stollman N; Rohlke F; Surawicz C
Am J Gastroenterol; 2012 Jul; 107(7):1079-87. PubMed ID: 22450732
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
32. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients.
Li Y; Qian J; Queener E; Shen B
Inflamm Bowel Dis; 2013 Feb; 19(2):397-403. PubMed ID: 23328770
[TBL] [Abstract][Full Text] [Related]
34. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
[TBL] [Abstract][Full Text] [Related]
35. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature.
Lin SC; Alonso CD; Moss AC
Transpl Infect Dis; 2018 Dec; 20(6):e12967. PubMed ID: 30011107
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
37. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Mitrovic N; Markovic A; Jordovic J; Katanic N; Barac A; Milosevic I
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):745-754. PubMed ID: 29299697
[TBL] [Abstract][Full Text] [Related]
38.
Dudzicz S; Kujawa-Szewieczek A; Kwiecień K; Więcek A; Adamczak M
Nutrients; 2018 Oct; 10(11):. PubMed ID: 30355985
[No Abstract] [Full Text] [Related]
39. Identification of Risk Factors Associated With Clostridium difficile Infection in Liver Transplantation Recipients: A Single-Center Analysis.
Rogala BG; Malat GE; Lee DH; Harhay MN; Doyle AM; Bias TE
Transplant Proc; 2016 Oct; 48(8):2763-2768. PubMed ID: 27788814
[TBL] [Abstract][Full Text] [Related]
40. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
